Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Myelodysplastic Syndrome
100%
Erythropoietin
36%
Multiple Myeloma
33%
Low-risk Myelodysplastic Syndromes
28%
Anemia
24%
RhEPO
24%
Erythropoiesis-stimulating Agents
19%
Israel
17%
Red Blood Cell Transfusion
16%
Transfusion Threshold
16%
Erythropoietin Therapy
15%
Lenalidomide
14%
Acute Myeloid Leukemia
11%
Thrombocytopenia
10%
Placebo
10%
Chemotherapy
10%
Myeloma
10%
Red Blood Cells
8%
Myelodysplasia
8%
Hemoglobin Level
8%
Platelet Count
8%
Azacitidine
8%
Heart Failure
8%
Higher-risk Myelodysplastic Syndromes
8%
Globin Genes
8%
European LeukemiaNet
8%
Acute Leukemia
7%
Internal Medicine
7%
Erythroid
7%
Platelets
7%
Eltrombopag
7%
Multiple Myeloma Patients
7%
Clinical Outcomes
7%
Chronic Myeloid Leukemia
7%
Dependent Patients
6%
Leukemia
6%
Erythropoietin Receptor
6%
Health-related Quality of Life
6%
T Cells
6%
Hemoglobin
6%
Granulocyte Colony-stimulating Factor (G-CSF)
6%
Thrombosis
6%
Transfusion Independence
6%
Secondary Myelodysplastic Syndrome
6%
Bone Loss
6%
Randomized Phase III Trial
6%
Platelet Function
6%
Europe
6%
Political Issues
6%
Blood Transfusion
6%
Medicine and Dentistry
Myelodysplastic Syndrome
86%
Diseases
18%
Anemia
14%
Infection
13%
Multiple Myeloma
13%
Platelet
11%
Erythrocyte
11%
Thrombocytopenia
11%
Erythropoietin
10%
Acute Myeloid Leukemia
10%
Azacitidine
10%
Quality of Life
8%
Hematinic
8%
Lenalidomide
7%
Hemoglobins
7%
Eltrombopag
7%
Internal Medicine
7%
Placebo
6%
Overall Survival
6%
Neoplasm
6%
Myeloma
6%
Thrombocyte Function
5%
Chemotherapy
5%
Acute Leukemia
5%